Skip to main content
Explore URMC

menu

Prostate Cancer: A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

Research Question:
What is the safety and anti-tumor effect of rucaparib with that of comparator treatment in patients with prostate cancer, and who have mutations in BRCA or ATM?

Basic Study Information

Purpose:
If you participate in this study, you will be assigned at random to receive treatment with either an experimental drug (called rucaparib) or one of the following comparator treatments: abiraterone acetate, enzalutamide, or docetaxel. If you are assigned to receive comparator treatment, your study doctor will help determine which one of the three therapy options is most appropriate for you. Approximately two thirds of the patients will be assigned to receive treatment with rucaparib and one-third will be assigned to receive comparator treatment.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02975934?term=triton3&recrs=ab&rank=1
Study Reference #: IGUP17020

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Guancial

Study Contact Information

Study Coordinator: Ayesha Khan
Phone: (585) 275-3351
Email: Ayesha_Khan@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Prostate Cancer

Return to Search